Welcome to deCODE diagnostics
deCODE, a global leader in gene discovery, is bringing to market a growing number of reference laboratory tests for genetic variants the company has linked to increased risk of developing common diseases. deCODE believes that such tests provide a novel means of better understanding individual risk of developing diseases such as type 2 diabetes, atrial fibrillation, heart attack and certain cancers.
deCODE currently offers deCODE T2™, which detects a single letter variation in the genome, or SNP, that deCODE has linked to increased likelihood of developing type 2 diabetes (T2D); deCODE AF™ , which detects versions of two SNPs that the company has linked to risk of atrial fibrillation (AF), a common cardiac arrhythmia that is a major risk factor for and cause of stroke; deCODE MI™, a test for increased risk for myocardial infarction (MI or heart attack), especially MI occurring at an early age, or before the age of 50 for men and 60 for women; deCODE Glaucoma™ detects SNP in the sequence of the LOXL1 gene that deCODE has linked to increased risk of one of the more common types of glaucoma, exfoliation type glaucoma; deCODE ProstateCancer™, which interrogates eight SNPs linked with prostate cancer risk and deCODE BreastCancer™ for assessing individual risk of the common forms of breast cancer.
For Physicians: |
For Patients: |
|
|
If you are a physician or healthcare professional
who would like to learn more about deCODE's tests
for inherited risk factors for common diseases, or
would like to order these tests for your patients,
please click here.
Access physician's site on deCODE tests >> |
If you are an individual and would like more information
on deCODE's DNA-based tests for better understanding
inherited risk of common diseases, please click here. Access patient's site on tests >> |
About deCODE
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases.